ArticleJACC. Case reports2026
Hereditary Transthyretin Cardiac Amyloidosis With Severe Left Ventricular Outflow Tract Obstruction Mimicking Hypertrophic Obstructive Cardiomyopathy.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac amyloidosis may mimic hypertrophic cardiomyopathy; however, severe left ventricular outflow tract (LVOT) obstruction is rarely described in transthyretin (TTR) cardiac amyloidosis. CASE SUMMARY: A 49-year-old man presented with exertional dyspnea and presyncope. Echocardiography demonstrated septal hypertrophy with severe LVOT obstruction, leading to an initial diagnosis of hypertrophic obstructive cardiomyopathy. Persistent symptoms prompted further evaluation. Cardiac magnetic resonance imaging revealed diffuse subendocardial late gadolinium enhancement, whereas bone scintigraphy demonstrated low-grade myocardial uptake. Genetic testing identified a pathogenic TTR variant, and endomyocardial biopsy confirmed TTR amyloidosis (ATTR). Tafamidis therapy was initiated, with clinical improvement during follow-up. DISCUSSION: Certain hereditary ATTR variants may present with low-grade tracer uptake, emphasizing the importance of tissue confirmation when suspicion persists. TAKE-HOME MESSAGES: Transthyretin-cardiac amyloidosis may mimic hypertrophic obstructive cardiomyopathy with severe LVOT obstruction. Certain hereditary ATTR variants may demonstrate low-grade tracer uptake on bone scintigraphy. Multimodality imaging, genetic testing, and tissue confirmation are essential when clinical suspicion persists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.